Interferon
Peginterferon alfa-2b plus ribavirin treatment evaluated in children with HPC
Published in Clinical Trials Week, June 27th, 2005
According to recent research published in the journal Hepatology, "Peginterferon plus ribavirin is standard therapy for adults with chronic HPC. As no data are available for children, the aim of the study was to evaluate the efficacy and tolerability of peginterferon alfa-2b in combination with ribavirin in chronically infected children."
"Genotypes, alanine aminotransferase levels, and different routes of viral transmission were considered. In an open-labeled, uncontrolled pilot study, 62 children and adolescents...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2005-06-27)
More Articles from Clinical Trials Week
- Non-Small Cell Lung Cancer
Celecoxib can be safely used concurrently with thoracic radiotherapy - Prostate Cancer
Combining recombinant cancer vaccine with radiotherapy is a safe regimen - Psoriatic Arthritis
Addition of cyclosporin to methotrexate treatment has limited effects - Acute Radiation Syndrome
New drug being developed for the treatment of acute radiation syndrome - Addiction Medicine
Harold Urschel to investigate protocols for treating methamphetamine dependence - Addiction Medicine
Lipid oxidative stress evaluated in bariatric candidates with NAFLD - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
